Cargando…

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis

The present study aimed to investigate the incidence of hepatocellular carcinoma (HCC) and factors related to HCC occurrence after direct-acting antiviral (DAA) treatment in the Fukushima Liver Academic Group (FLAG). We conducted a multicenter retrospective cohort study of 1068 patients without cirr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abe, Kazumichi, Wakabayashi, Hiroto, Nakayama, Haruo, Suzuki, Tomohiro, Kuroda, Masahito, Yoshida, Naoe, Tojo, Jun, Kogure, Atsuko, Rai, Tsuyoshi, Saito, Hironobu, Mukai, Shinji, Fujita, Masashi, Hayashi, Manabu, Takahashi, Atsushi, Ohira, Hiromasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721183/ https://www.ncbi.nlm.nih.gov/pubmed/33284844 http://dx.doi.org/10.1371/journal.pone.0243473

Ejemplares similares

The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy
por: Abe, Kazumichi, et al.
Publicado: (2021)

Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis
por: Fujita, Masashi, et al.
Publicado: (2020)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Characterization of Autoantibodies against the E1α Subunit of Branched-Chain 2-Oxoacid Dehydrogenase in Patients with Primary Biliary Cirrhosis
por: Mori, Tsutomu, et al.
Publicado: (2012)

Arterial Blood Pressure Is Closely Related to Ascites Development in Compensated HCV-Related Cirrhosis
por: Vilar Gomez, Eduardo, et al.
Publicado: (2014)

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
por: Merchante, Nicolás, et al.
Publicado: (2015)

Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2016)

Liver stiffness and thrombin generation in compensated cirrhosis
por: Dillon, Audrey, et al.
Publicado: (2019)

British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 1: compensated cirrhosis
por: Mansour, Dina, et al.
Publicado: (2023)

Small Bowel Abnormalities in Patients with Compensated Liver Cirrhosis
por: Aoyama, Taiki, et al.
Publicado: (2012)

Correction: Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2018)

Duodenal Permeability Is Associated With Mucosal Microbiota in Compensated Cirrhosis
por: Bloom, P.P., et al.
Publicado: (2022)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
por: Cornberg, Markus, et al.
Publicado: (2022)

Immunologic Characterization of Posthepatitis Cirrhosis Caused by HBV and HCV Infection
por: Li, Wan-Yu, et al.
Publicado: (2010)

Myelodysplastic syndrome in a patient with HCV cirrhosis. Case report
por: Olariu, Mihai, et al.
Publicado: (2013)

Hepatocyte Turnover in Chronic HCV-Induced Liver Injury and Cirrhosis
por: Karidis, Nikolaos P., et al.
Publicado: (2015)

Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis
por: King, Lindsay Y., et al.
Publicado: (2014)

Need to Face Liver Cirrhosis after HCV Cure with Antivirals
por: Soriano, Vicente, et al.
Publicado: (2017)

The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals
por: Seko, Yuya, et al.
Publicado: (2020)

Frequency of minimal hepatic encepalopathy in illeterate patients with compensated cirrhosis
por: Zuberi, Bader Faiyaz, et al.
Publicado: (2016)

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017)

Compensated liver cirrhosis: Natural course and disease-modifying strategies
por: Kumar, Ramesh, et al.
Publicado: (2023)

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)
por: Asselah, Tarik, et al.
Publicado: (2019)

Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers
por: Safaei, Akram, et al.
Publicado: (2020)

SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
por: Kaplan, David E., et al.
Publicado: (2021)

Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment
por: Mihai, Florin, et al.
Publicado: (2020)

Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study
por: Buscail, Camille, et al.
Publicado: (2018)

Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated Cirrhosis
por: Balakrishnan, Maya, et al.
Publicado: (2021)

Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
por: Thanapirom, Kessarin, et al.
Publicado: (2021)

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis
por: Reiberger, Thomas
Publicado: (2021)

Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
por: McGill, Mitchell R., et al.
Publicado: (2021)

Pregnancy Is Not Associated with an Increased Risk of Decompensation, Transplant, or Death in Compensated Cirrhosis
por: Mullin, Monica, et al.
Publicado: (2022)

Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
por: Chen, Qingling, et al.
Publicado: (2023)

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

The Survival of Septic Patients with Compensated Liver Cirrhosis Is Not Inferior to That of Septic Patients without Liver Cirrhosis: A Propensity Score Matching Analysis
por: Chang, Ya-Chun, et al.
Publicado: (2022)

Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
por: Trifan, Anca, et al.
Publicado: (2017)

Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis
por: Federico, Alessandro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d0qo8pbrhpov95tm6j1p4i201b